首页 > 最新文献

Journal of Pharmacology and Pharmacotherapeutics最新文献

英文 中文
Management of Kampavata (Parkinson’s Disease) Through Panchakarma: A Successful Case Study 通过潘查卡玛疗法治疗帕金森病:成功案例研究
Pub Date : 2024-08-10 DOI: 10.1177/0976500x241266049
Sonia Mandal, P. Sawarkar, Varinder Singh, Shweta Parwe, G. Sawarkar
Parkinson’s disease (PD) affects the central nervous system and is primarily characterized by the degeneration of dopamine-producing cells in the substantia nigra. Early signs include tremor, rigidity, bradykinesia, and postural instability, with later cognitive, sensory, sleep, and emotional issues. Ayurveda correlates these symptoms with Kampavata, primarily linked to Vata (bio-entities) imbalance. The prime aim of this paper is to study Panchakarma’s efficacy in managing Kampavata (PD). This is a case presentation of a 55-year-old male patient who has experienced tremors in the left upper and lower limbs, numbness in the left lower limb, loss of balance for 10 years, abnormal facial expression (masked face), difficulty in speech, and sleep disturbance for 5 years. The patient was treated with Panchakarma therapy for 30 days. Following treatment, the patient exhibited significant improvement in symptoms, assessed using the PD composite scale, with the total score decreasing from 68 to 19, along with evaluated by specific examination, bradykinesia test, reflexes, functional activities, and clinical features also notably improved. Panchakarma therapy, rooted in Ayurvedic principles, shows promise in managing Kampavata, associated with PD. Conservative management focuses on Vata balance, which offers substantial comfort and enhances patient quality of life. Panchakarma therapy presents a potential avenue for treating Kampavata, addressing symptoms associated with PD, and improving patient satisfaction and well-being. Further research is warranted to validate these findings and explore the broader applicability of Ayurvedic approaches in neurodegenerative conditions.
帕金森病(PD)影响中枢神经系统,主要特征是黑质中产生多巴胺的细胞发生变性。早期症状包括震颤、僵直、运动迟缓和姿势不稳,随后会出现认知、感官、睡眠和情绪问题。阿育吠陀将这些症状与 Kampavata 相关联,主要与 Vata(生物实体)失衡有关。本文的主要目的是研究潘查卡玛疗法在控制坎帕瓦塔(PD)方面的疗效。这是一个 55 岁男性患者的病例,该患者左上下肢震颤、左下肢麻木、失去平衡达 10 年之久,面部表情异常(面具脸)、言语困难和睡眠障碍已有 5 年之久。患者接受了为期 30 天的潘查卡玛疗法。治疗后,患者的症状明显改善,根据帕金森病综合量表进行评估,总分从 68 分降至 19 分,具体检查、运动迟缓试验、反射、功能活动和临床特征也明显改善。根植于阿育吠陀学原理的潘查卡玛疗法有望控制与帕金森病相关的坎帕瓦塔。保守治疗侧重于瓦塔(Vata)平衡,可为患者带来极大的舒适感并提高其生活质量。潘查卡玛疗法为治疗坎帕瓦塔、解决与帕金森病相关的症状、提高患者满意度和幸福感提供了一条潜在的途径。为了验证这些发现并探索阿育吠陀疗法在神经退行性疾病中更广泛的适用性,我们有必要开展进一步的研究。
{"title":"Management of Kampavata (Parkinson’s Disease) Through Panchakarma: A Successful Case Study","authors":"Sonia Mandal, P. Sawarkar, Varinder Singh, Shweta Parwe, G. Sawarkar","doi":"10.1177/0976500x241266049","DOIUrl":"https://doi.org/10.1177/0976500x241266049","url":null,"abstract":"Parkinson’s disease (PD) affects the central nervous system and is primarily characterized by the degeneration of dopamine-producing cells in the substantia nigra. Early signs include tremor, rigidity, bradykinesia, and postural instability, with later cognitive, sensory, sleep, and emotional issues. Ayurveda correlates these symptoms with Kampavata, primarily linked to Vata (bio-entities) imbalance. The prime aim of this paper is to study Panchakarma’s efficacy in managing Kampavata (PD). This is a case presentation of a 55-year-old male patient who has experienced tremors in the left upper and lower limbs, numbness in the left lower limb, loss of balance for 10 years, abnormal facial expression (masked face), difficulty in speech, and sleep disturbance for 5 years. The patient was treated with Panchakarma therapy for 30 days. Following treatment, the patient exhibited significant improvement in symptoms, assessed using the PD composite scale, with the total score decreasing from 68 to 19, along with evaluated by specific examination, bradykinesia test, reflexes, functional activities, and clinical features also notably improved. Panchakarma therapy, rooted in Ayurvedic principles, shows promise in managing Kampavata, associated with PD. Conservative management focuses on Vata balance, which offers substantial comfort and enhances patient quality of life. Panchakarma therapy presents a potential avenue for treating Kampavata, addressing symptoms associated with PD, and improving patient satisfaction and well-being. Further research is warranted to validate these findings and explore the broader applicability of Ayurvedic approaches in neurodegenerative conditions.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141920243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-inflammatory Property of Ethanolic Extract 
of Cleome spinosa Leaves in an In Vivo Model of Delayed-type Hypersensitivity 在延迟型超敏反应体内模型中的辣木叶乙醇提取物的抗炎特性
Pub Date : 2024-06-08 DOI: 10.1177/0976500x241253645
Torisa Roy, T. Mazumder, Priyanka Sharma, Tamali Roy, T. Nag, Samik Bindu, S. Dasgupta, H. Yasmin
Delayed-type hypersensitivity (DTH) reactions represent a clinically important class of immune responses that have wide-ranging implications in various health and disease conditions. The existing anti-inflammatory drugs to treat DTH have several shortcomings including severe side-effects. Thus, a new plant-derived anti-inflammatory drug with no or less toxicity would be effective in treating DTH. The Cleome genus has been routinely used to cure various ailments including inflammation. This study investigates the anti-inflammatory properties of the ethanolic leaf extract of Cleome spinosa (CSE) in a DTH model for the first time. DTH response was induced by 2, 4-di nitro-fluorobenzene in the mouse foot pad. Histological sectioning of the paw was carried out to find changes in the architecture of the tissue. Serum tumour necrosis factor-alpha (TNF-α) was estimated through enzyme linked immunosorbent assay (ELISA), and the bioactive compounds present in CSE were analysed through reversed phase-high-performance liquid chromatography . With CSE treatment, the oedema in the resensitized paw alleviated faster with no loss of digits compared to the controls. Histological study of the resensitized paw showed less dermal and sub-dermal thickening and less collagen deposition that regained normal tissue architecture during the healing process with CSE treatment. CSE treatment did not show any adverse haematological and histopathological changes in the visceral organs of mice. The level of serum TNF-α was found to be significantly lower with CSE treatment. CSE was found to be rich in phenol, flavonoids, tocopherol, carotene and phytosteroids. The anti-inflammatory and immunomodulatory role of CSE against hapten-induced deleterious DTH inflammation suggests its therapeutic potential in treating inflammatory diseases and combating infections.
迟发型超敏反应(DTH)是临床上一类重要的免疫反应,对各种健康和疾病状况有着广泛的影响。现有的治疗 DTH 的抗炎药物存在一些缺点,包括严重的副作用。因此,一种无毒或毒性较低的新型植物提取抗炎药物可有效治疗 DTH。艳紫铆属植物已被常规用于治疗包括炎症在内的各种疾病。本研究首次在 DTH 模型中研究了刺牛膝(Cleome spinosa,CSE)乙醇叶提取物的抗炎特性。2,4-二硝基氟苯诱导了小鼠足垫的 DTH 反应。对脚掌进行组织学切片,以发现组织结构的变化。通过酶联免疫吸附试验(ELISA)对血清肿瘤坏死因子-α(TNF-α)进行估计,并通过反相高效液相色谱法对 CSE 中的生物活性化合物进行分析。与对照组相比,经过 CSE 治疗后,再敏化爪子的水肿缓解得更快,且没有出现指头缺失的情况。对复敏爪的组织学研究显示,在 CSE 治疗的愈合过程中,真皮和皮下增厚较少,胶原沉积较少,组织结构恢复正常。CSE 处理未对小鼠的内脏器官造成任何不利的血液学和组织病理学变化。经 CSE 治疗后,小鼠血清 TNF-α 水平明显降低。研究发现 CSE 含有丰富的酚类、类黄酮、生育酚、胡萝卜素和植物固醇。CSE 对合蛋白诱导的有害 DTH 炎症具有抗炎和免疫调节作用,这表明它在治疗炎症性疾病和抗感染方面具有治疗潜力。
{"title":"Anti-inflammatory Property of Ethanolic Extract \u2028of Cleome spinosa Leaves in an In Vivo Model of Delayed-type Hypersensitivity","authors":"Torisa Roy, T. Mazumder, Priyanka Sharma, Tamali Roy, T. Nag, Samik Bindu, S. Dasgupta, H. Yasmin","doi":"10.1177/0976500x241253645","DOIUrl":"https://doi.org/10.1177/0976500x241253645","url":null,"abstract":"Delayed-type hypersensitivity (DTH) reactions represent a clinically important class of immune responses that have wide-ranging implications in various health and disease conditions. The existing anti-inflammatory drugs to treat DTH have several shortcomings including severe side-effects. Thus, a new plant-derived anti-inflammatory drug with no or less toxicity would be effective in treating DTH. The Cleome genus has been routinely used to cure various ailments including inflammation. This study investigates the anti-inflammatory properties of the ethanolic leaf extract of Cleome spinosa (CSE) in a DTH model for the first time. DTH response was induced by 2, 4-di nitro-fluorobenzene in the mouse foot pad. Histological sectioning of the paw was carried out to find changes in the architecture of the tissue. Serum tumour necrosis factor-alpha (TNF-α) was estimated through enzyme linked immunosorbent assay (ELISA), and the bioactive compounds present in CSE were analysed through reversed phase-high-performance liquid chromatography . With CSE treatment, the oedema in the resensitized paw alleviated faster with no loss of digits compared to the controls. Histological study of the resensitized paw showed less dermal and sub-dermal thickening and less collagen deposition that regained normal tissue architecture during the healing process with CSE treatment. CSE treatment did not show any adverse haematological and histopathological changes in the visceral organs of mice. The level of serum TNF-α was found to be significantly lower with CSE treatment. CSE was found to be rich in phenol, flavonoids, tocopherol, carotene and phytosteroids. The anti-inflammatory and immunomodulatory role of CSE against hapten-induced deleterious DTH inflammation suggests its therapeutic potential in treating inflammatory diseases and combating infections.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":" 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141370800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurotoxicity by Hypoxia an Intermediate Between Alpha-synuclein and Mitochondrial Dysfunction in Parkinson’s Disease 缺氧导致的神经毒性是帕金森病中α-突触核蛋白和线粒体功能障碍的中间产物
Pub Date : 2024-06-08 DOI: 10.1177/0976500x241253648
Jagdish Chand, Hannah Lalengzuali Fanai, A. S. Antony, Gomathy Subramanian
This review article explores the relationship between alpha-synuclein and mitochondrial dysfunction in Parkinson’s disease (PD), focusing on the role of hypoxia as an intermediate factor. The interaction between alpha-synuclein and mitochondria, particularly through membranal lipids such as cardiolipins, is highlighted as a key factor in mitochondrial disruption and neurodegeneration. Hypoxia, caused by oxygen deprivation, is identified as a crucial link between alpha-synuclein and mitochondrial regulation, leading to neuronal death in PD. The article also discusses the involvement of other proteins, such as peroxisome proliferator-activated receptor gamma coactivator, Sirtuin-1, Sirtuin-3 and adenosine monophosphate-activated protein kinase, in maintaining mitochondrial biogenesis during hypoxia. The study emphasizes the need for further research to understand the complex molecular interactions causing Lewy body aggregation, improper mitochondrial functioning and neurodegeneration in PD, with a specific focus on the role of hypoxia. Alpha-synuclein aggregation disrupts mitochondrial respiration, leading to mitochondrial dysfunction and increased production of reactive oxygen species. Mitochondrial dysfunction, in turn, causes neurodegeneration in PD. Oligomeric alpha-synuclein results in mitochondrial dysfunction, lethal synaptic disruption and reduced adenosine triphosphate generation. Oligomeric alpha-synuclein also increases the accumulation of mitochondrial rho nucleotide guanosine triphosphate, leading to delayed mitophagy. Hypoxia, another factor in PD, alters both alpha-synuclein and mitochondria. Controlling hypoxia reduces the oligomerization of alpha-synuclein. The interaction between alpha-synuclein and mitochondria is complex, and determining the primary player in inducing the other is still debatable.
这篇综述文章探讨了帕金森病(PD)中α-突触核蛋白与线粒体功能障碍之间的关系,重点关注缺氧作为中间因素的作用。α-突触核蛋白与线粒体之间的相互作用,特别是通过膜脂质(如心磷脂)的相互作用,被强调为线粒体破坏和神经退行性变的关键因素。缺氧是α-突触核蛋白和线粒体调节之间的关键环节,导致帕金森病神经元死亡。文章还讨论了其他蛋白质,如过氧化物酶体增殖激活受体γ辅激活因子、Sirtuin-1、Sirtuin-3和单磷酸腺苷激活的蛋白激酶,在缺氧过程中参与维持线粒体的生物生成。该研究强调,有必要进一步研究导致路易体聚集、线粒体功能失调和帕金森病神经退行性变的复杂分子相互作用,并特别关注缺氧的作用。α-突触核蛋白聚集会破坏线粒体呼吸,导致线粒体功能障碍和活性氧生成增加。线粒体功能障碍反过来又会导致帕金森病的神经变性。寡聚α-突触核蛋白会导致线粒体功能障碍、致命的突触破坏和三磷酸腺苷生成减少。寡聚α-突触核蛋白还会增加线粒体 rho 核苷酸三磷酸鸟苷的积累,导致有丝分裂延迟。缺氧是导致帕金森病的另一个因素,它同时改变了α-突触核蛋白和线粒体。控制缺氧可减少α-突触核蛋白的寡聚化。α-突触核蛋白和线粒体之间的相互作用非常复杂,确定诱导二者的主要角色仍有争议。
{"title":"Neurotoxicity by Hypoxia an Intermediate Between Alpha-synuclein and Mitochondrial Dysfunction in Parkinson’s Disease","authors":"Jagdish Chand, Hannah Lalengzuali Fanai, A. S. Antony, Gomathy Subramanian","doi":"10.1177/0976500x241253648","DOIUrl":"https://doi.org/10.1177/0976500x241253648","url":null,"abstract":"This review article explores the relationship between alpha-synuclein and mitochondrial dysfunction in Parkinson’s disease (PD), focusing on the role of hypoxia as an intermediate factor. The interaction between alpha-synuclein and mitochondria, particularly through membranal lipids such as cardiolipins, is highlighted as a key factor in mitochondrial disruption and neurodegeneration. Hypoxia, caused by oxygen deprivation, is identified as a crucial link between alpha-synuclein and mitochondrial regulation, leading to neuronal death in PD. The article also discusses the involvement of other proteins, such as peroxisome proliferator-activated receptor gamma coactivator, Sirtuin-1, Sirtuin-3 and adenosine monophosphate-activated protein kinase, in maintaining mitochondrial biogenesis during hypoxia. The study emphasizes the need for further research to understand the complex molecular interactions causing Lewy body aggregation, improper mitochondrial functioning and neurodegeneration in PD, with a specific focus on the role of hypoxia. Alpha-synuclein aggregation disrupts mitochondrial respiration, leading to mitochondrial dysfunction and increased production of reactive oxygen species. Mitochondrial dysfunction, in turn, causes neurodegeneration in PD. Oligomeric alpha-synuclein results in mitochondrial dysfunction, lethal synaptic disruption and reduced adenosine triphosphate generation. Oligomeric alpha-synuclein also increases the accumulation of mitochondrial rho nucleotide guanosine triphosphate, leading to delayed mitophagy. Hypoxia, another factor in PD, alters both alpha-synuclein and mitochondria. Controlling hypoxia reduces the oligomerization of alpha-synuclein. The interaction between alpha-synuclein and mitochondria is complex, and determining the primary player in inducing the other is still debatable.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":" 47","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141370260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of Ascorbic Acid on Di-(2-Ethylhexyl) Phthalate-induced Ovarian Gene Alterations in Pubertal Female Wistar Rats 抗坏血酸对邻苯二甲酸二(2-乙基己基)酯诱导的青春期雌性 Wistar 大鼠卵巢基因改变的影响
Pub Date : 2024-05-16 DOI: 10.1177/0976500x241245481
Shifana Ali, Ahmed Ziyad, K. S. R. Pai, Anju Muraleedharan, Adhithya Gopan, Raghavendra Upadhya, R. Seetharam, K. Manokaran
Di-(2-ethylhexyl) phthalate (DEHP), a plasticizer compound affecting female reproduction, leads to scenarios, such as polycystic ovarian syndrome (PCOS) and infertility through oxidative stress (OS) mechanisms. Ascorbic acid (AA) is one of the antioxidants in infertility issues. The present study investigates the ameliorative effect of AA on DEHP-induced ovarian toxicity in pubertal female Wistar rats. Thirty female Wistar rats of four weeks of age were stratified into five groups. Group I was treated with corn oil (Vehicle), groups II and III with low and high dose DEHP, and groups IV and V with low and high dose DEHP+AA were administered for 30 days. Increased body weight gain was noted in DEHP groups. Estradiol hormone was considerably reduced, whereas progesterone levels were increased in both low- and high-dose DEHP-treated groups. DEHP+AA groups have shown significant ( p < 0.005) protection of these hormone levels as equal to the control group. The high-dose DEHP group shows an increased, ovarian estrogen receptor (ER) alpha, ER-beta, and progesterone receptor gene expression, and DEHP+AA groups have significantly ( p < 0.005) showed expression similar to the control. OS was noted with decreased superoxide dismutase and increased malondialdehyde expression in Group III (GR III) compared to control, whereas the DEHP+AA treated group significantly protected OS by restoring the expression levels. DEHP-treated groups show elevated levels of both Bcl-2 and BAX which is specific to apoptotic expression and restored by AA treatment ( p < 0.005). Evidence suggests that AA may protect against DEHP-induced ovarian toxicity by decreasing OS levels, improving folliculogenesis, and restoring the hormonal with receptor level alterations.
邻苯二甲酸二(2-乙基己基)酯(DEHP)是一种影响女性生殖的增塑剂化合物,通过氧化应激(OS)机制导致多囊卵巢综合症(PCOS)和不孕症等情况。抗坏血酸(AA)是治疗不孕症的抗氧化剂之一。本研究调查了 AA 对 DEHP 诱导的青春期雌性 Wistar 大鼠卵巢毒性的改善作用。将 30 只四周龄的雌性 Wistar 大鼠分为五组。I 组使用玉米油(载体),II 组和 III 组使用低剂量和高剂量 DEHP,IV 组和 V 组使用低剂量和高剂量 DEHP+AA,连续用药 30 天。DEHP 组的体重增加。低剂量和高剂量 DEHP 组的雌二醇激素水平显著下降,而孕酮水平上升。与对照组相比,DEHP+AA 组对这些激素水平有明显的保护作用(p < 0.005)。高剂量 DEHP 组显示卵巢雌激素受体(ER)α、ER-β 和孕酮受体基因表达增加,而 DEHP+AA 组则显示与对照组相似的基因表达(p < 0.005)。与对照组相比,第 III 组(GR III)的超氧化物歧化酶减少,丙二醛表达增加,而 DEHP+AA 处理组通过恢复表达水平显著保护了 OS。DEHP处理组的Bcl-2和BAX水平升高,这是凋亡表达的特异性表现,经AA处理后得到恢复(P < 0.005)。有证据表明,AA可通过降低OS水平、改善卵泡生成和恢复激素与受体水平的改变来防止DEHP诱导的卵巢毒性。
{"title":"Influence of Ascorbic Acid on Di-(2-Ethylhexyl) Phthalate-induced Ovarian Gene Alterations in Pubertal Female Wistar Rats","authors":"Shifana Ali, Ahmed Ziyad, K. S. R. Pai, Anju Muraleedharan, Adhithya Gopan, Raghavendra Upadhya, R. Seetharam, K. Manokaran","doi":"10.1177/0976500x241245481","DOIUrl":"https://doi.org/10.1177/0976500x241245481","url":null,"abstract":"Di-(2-ethylhexyl) phthalate (DEHP), a plasticizer compound affecting female reproduction, leads to scenarios, such as polycystic ovarian syndrome (PCOS) and infertility through oxidative stress (OS) mechanisms. Ascorbic acid (AA) is one of the antioxidants in infertility issues. The present study investigates the ameliorative effect of AA on DEHP-induced ovarian toxicity in pubertal female Wistar rats. Thirty female Wistar rats of four weeks of age were stratified into five groups. Group I was treated with corn oil (Vehicle), groups II and III with low and high dose DEHP, and groups IV and V with low and high dose DEHP+AA were administered for 30 days. Increased body weight gain was noted in DEHP groups. Estradiol hormone was considerably reduced, whereas progesterone levels were increased in both low- and high-dose DEHP-treated groups. DEHP+AA groups have shown significant ( p < 0.005) protection of these hormone levels as equal to the control group. The high-dose DEHP group shows an increased, ovarian estrogen receptor (ER) alpha, ER-beta, and progesterone receptor gene expression, and DEHP+AA groups have significantly ( p < 0.005) showed expression similar to the control. OS was noted with decreased superoxide dismutase and increased malondialdehyde expression in Group III (GR III) compared to control, whereas the DEHP+AA treated group significantly protected OS by restoring the expression levels. DEHP-treated groups show elevated levels of both Bcl-2 and BAX which is specific to apoptotic expression and restored by AA treatment ( p < 0.005). Evidence suggests that AA may protect against DEHP-induced ovarian toxicity by decreasing OS levels, improving folliculogenesis, and restoring the hormonal with receptor level alterations.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":"20 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140966834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the Novel Therapeutic Potential of N-acetylcysteine in Depression, Bipolar Disorders, and Anxiety 探索 N-乙酰半胱氨酸对抑郁症、双相情感障碍和焦虑症的新治疗潜力
Pub Date : 2024-05-16 DOI: 10.1177/0976500x241246402
Reuben P. Syiem, J. Wahlang, Krishnamoorthi R., Pavan B. Kalyan, Diana Nahakpam, A. J. Langstieh
Anxiety disorders, bipolar disorder, and depression are prevalent mental health issues that have a substantial impact on both individuals and the community. Many people continue to have symptoms and do not get the right kind of relief from their existing drugs, even after trying conventional therapy methods. Therefore, to enhance the current treatment modalities and patient results, new therapeutic alternatives are required. In recent years, there has been an increase in interest in N-acetylcysteine (NAC) because of its many biological benefits, including its ability to modulate glutamate levels and its antioxidant and anti-inflammatory properties. According to studies, NAC has encouraging antidepressant properties and may help treat bipolar disease by stabilizing mood and reducing the risk of relapses. Furthermore, through lowering oxidative stress and modifying neurotransmitter networks, NAC has been shown to lessen the symptoms of anxiety. The preclinical and clinical research examining the efficacy of NAC in depression, bipolar disorders, and anxiety are thoroughly analyzed in this review. Books were reviewed and medical and scientific literature found in MEDLINE and PubMed were analyzed for an assessment of NAC’s therapeutic potential in psychiatric illnesses such as anxiety, depression, and bipolar disorder. NAC exhibits potential as a therapeutic agent for psychiatric problems such as anxiety, bipolar disorder, and depression. Performing a thorough clinical study will facilitate proper understanding its efficacy, safety and mechanisms of action.
焦虑症、躁郁症和抑郁症是普遍存在的精神健康问题,对个人和社会都有很大影响。许多人在尝试了传统的治疗方法后,症状依然存在,现有的药物也无法起到应有的缓解作用。因此,为了改善目前的治疗模式和病人的治疗效果,需要新的治疗替代方法。近年来,人们对 N-乙酰半胱氨酸(NAC)的兴趣日益浓厚,因为它具有多种生物学益处,包括调节谷氨酸水平的能力以及抗氧化和抗炎特性。根据研究,NAC 具有令人鼓舞的抗抑郁特性,可通过稳定情绪和降低复发风险来帮助治疗躁郁症。此外,通过降低氧化应激和改变神经递质网络,NAC 还能减轻焦虑症状。本综述全面分析了 NAC 对抑郁症、躁郁症和焦虑症疗效的临床前和临床研究。我们查阅了相关书籍,并分析了 MEDLINE 和 PubMed 上的医学和科学文献,以评估 NAC 对焦虑症、抑郁症和躁狂症等精神疾病的治疗潜力。NAC 具有治疗焦虑症、躁郁症和抑郁症等精神疾病的潜力。进行彻底的临床研究将有助于正确理解其疗效、安全性和作用机制。
{"title":"Exploring the Novel Therapeutic Potential of N-acetylcysteine in Depression, Bipolar Disorders, and Anxiety","authors":"Reuben P. Syiem, J. Wahlang, Krishnamoorthi R., Pavan B. Kalyan, Diana Nahakpam, A. J. Langstieh","doi":"10.1177/0976500x241246402","DOIUrl":"https://doi.org/10.1177/0976500x241246402","url":null,"abstract":"Anxiety disorders, bipolar disorder, and depression are prevalent mental health issues that have a substantial impact on both individuals and the community. Many people continue to have symptoms and do not get the right kind of relief from their existing drugs, even after trying conventional therapy methods. Therefore, to enhance the current treatment modalities and patient results, new therapeutic alternatives are required. In recent years, there has been an increase in interest in N-acetylcysteine (NAC) because of its many biological benefits, including its ability to modulate glutamate levels and its antioxidant and anti-inflammatory properties. According to studies, NAC has encouraging antidepressant properties and may help treat bipolar disease by stabilizing mood and reducing the risk of relapses. Furthermore, through lowering oxidative stress and modifying neurotransmitter networks, NAC has been shown to lessen the symptoms of anxiety. The preclinical and clinical research examining the efficacy of NAC in depression, bipolar disorders, and anxiety are thoroughly analyzed in this review. Books were reviewed and medical and scientific literature found in MEDLINE and PubMed were analyzed for an assessment of NAC’s therapeutic potential in psychiatric illnesses such as anxiety, depression, and bipolar disorder. NAC exhibits potential as a therapeutic agent for psychiatric problems such as anxiety, bipolar disorder, and depression. Performing a thorough clinical study will facilitate proper understanding its efficacy, safety and mechanisms of action.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":"20 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140967299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Systematic Review and Meta-analysis of Selective Cyclooxygenase-2 Inhibitors and Non-selective Non-steroidal Anti-inflammatory Drugs for Acute Gout 治疗急性痛风的选择性环氧化酶-2 抑制剂和非选择性非甾体抗炎药物的系统回顾和 Meta 分析
Pub Date : 2024-05-14 DOI: 10.1177/0976500x241240629
Swathy Govindaswamy, Kavya Ponnusamy, Indhumathi *S., Vineeth Anil, Jayalakshmi Venugopal, Dhivya P. Sundaram
Background:The term “gout” refers to a broad clinical spectrum of diseases, including common and complex forms of arthritis, that affect multiple joints in a patient due to an elevated serum urate concentration. Purpose: The study aims to compare the efficacy and safety of selective cyclooxygenase-2 (COX-2) inhibitors and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of acute gout, as well as to conduct a meta-analysis on safety. Methods: As of December 2021, the literature search was conducted using authorised electronic databases such as PubMed, Embase, Web of Science, and the Cochrane Library. Results: There were seven investigations included in this study’s findings. Three COX-2 inhibitors, etoricoxib, celecoxib, and meloxicam, were reportedly compared to indomethacin or diclofenac. Four hours after the initial dose, 120 mg of etoricoxib reduces pain and inflammation by diminishing erythema. At higher dosages, celecoxib is more effective than at lower doses. Meloxicam has the same efficacy as NSAIDs. The subgroup analysis revealed that the risk of adverse events was 8.0% lower in the COX-2 inhibitors group than in the non-selective NSAIDs group (risk ratio = 0.92, 95% confidence interval = 0.60 to 0.40, p-value = 0.5). Conclusion: Etoricoxib, a COX-2 inhibitor, has a more potent effect and may be more effective than nonselective NSAIDs. COX-2 inhibitors are more well tolerated and reduce the risk of adverse gastrointestinal events more effectively than nonselective NSAIDs. In the treatment of gout, nonselective NSAIDs may be a suitable alternative to COX-2 inhibitors.
背景:"痛风 "一词是指由于血清尿酸盐浓度升高而影响患者多个关节的广泛临床疾病,包括常见和复杂形式的关节炎。目的:本研究旨在比较选择性环氧化酶-2(COX-2)抑制剂和非选择性非甾体抗炎药(NSAIDs)治疗急性痛风的疗效和安全性,并对安全性进行荟萃分析。研究方法截至 2021 年 12 月,使用 PubMed、Embase、Web of Science 和 Cochrane Library 等授权电子数据库进行文献检索。结果本研究结果共纳入了七项调查。据报道,三种 COX-2 抑制剂(依托考昔、塞来昔布和美洛昔康)与吲哚美辛或双氯芬酸进行了比较。首次用药四小时后,120 毫克依托考昔可通过减少红斑来减轻疼痛和炎症。较高剂量的塞来昔布比较低剂量的塞来昔布更有效。美洛昔康的疗效与非甾类抗炎药相同。亚组分析显示,COX-2 抑制剂组发生不良事件的风险比非选择性非甾体抗炎药组低 8.0%(风险比 = 0.92,95% 置信区间 = 0.60 至 0.40,P 值 = 0.5)。结论COX-2抑制剂依托考昔的作用更强,可能比非选择性非甾体抗炎药更有效。与非选择性非甾体抗炎药相比,COX-2 抑制剂的耐受性更好,能更有效地降低胃肠道不良反应的风险。在痛风的治疗中,非选择性非甾体抗炎药可能是 COX-2 抑制剂的合适替代品。
{"title":"A Systematic Review and Meta-analysis of Selective Cyclooxygenase-2 Inhibitors and Non-selective Non-steroidal Anti-inflammatory Drugs for Acute Gout","authors":"Swathy Govindaswamy, Kavya Ponnusamy, Indhumathi *S., Vineeth Anil, Jayalakshmi Venugopal, Dhivya P. Sundaram","doi":"10.1177/0976500x241240629","DOIUrl":"https://doi.org/10.1177/0976500x241240629","url":null,"abstract":"Background:The term “gout” refers to a broad clinical spectrum of diseases, including common and complex forms of arthritis, that affect multiple joints in a patient due to an elevated serum urate concentration. Purpose: The study aims to compare the efficacy and safety of selective cyclooxygenase-2 (COX-2) inhibitors and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of acute gout, as well as to conduct a meta-analysis on safety. Methods: As of December 2021, the literature search was conducted using authorised electronic databases such as PubMed, Embase, Web of Science, and the Cochrane Library. Results: There were seven investigations included in this study’s findings. Three COX-2 inhibitors, etoricoxib, celecoxib, and meloxicam, were reportedly compared to indomethacin or diclofenac. Four hours after the initial dose, 120 mg of etoricoxib reduces pain and inflammation by diminishing erythema. At higher dosages, celecoxib is more effective than at lower doses. Meloxicam has the same efficacy as NSAIDs. The subgroup analysis revealed that the risk of adverse events was 8.0% lower in the COX-2 inhibitors group than in the non-selective NSAIDs group (risk ratio = 0.92, 95% confidence interval = 0.60 to 0.40, p-value = 0.5). Conclusion: Etoricoxib, a COX-2 inhibitor, has a more potent effect and may be more effective than nonselective NSAIDs. COX-2 inhibitors are more well tolerated and reduce the risk of adverse gastrointestinal events more effectively than nonselective NSAIDs. In the treatment of gout, nonselective NSAIDs may be a suitable alternative to COX-2 inhibitors.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":"64 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140979088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Pharmacotherapy of Cancer 
Pain in Patients with Head and Neck Cancer 
at a Tertiary Care Teaching Hospital 对一家三级教学医院头颈癌患者癌症疼痛药物治疗的评估
Pub Date : 2024-05-14 DOI: 10.1177/0976500x241246414
Shyam Vacchani, Megha Shah, Chetna Desai, Priti Sanghvi
Head and neck cancers (HNC) account for 5% of all malignant tumours, but 80% of patients experience pain. As per the WHO analgesic ladder, analgesics are a cornerstone for the management of pain in HNC patients. Our study aims to analyse the prescribing pattern of analgesic drugs in patients with HNC pain. A prospective, continuous, observational study was conducted among patients with HNC pain. Demographics, detailed history of pain (type, duration, location and Numerical Rating Scale [NRS] score), details of drugs prescribed and any adverse drug reactions (ADRs) were recorded at baseline visit and at first, second and sixth month follow-up. Descriptive statistics were used to analyse the above parameters. The mean reduction in NRS was analysed by the Z test. Out of 145 patients, 118 (81.37%) were male and 27 (18.62%) were female. The mean age of patients was 51.89 + 7.07 years. Tramadol (81.37%) followed by morphine (62.75%) were the commonly prescribed analgesics. Amitriptyline (20%) followed by pregabalin (19.31%) were commonly prescribed adjuvant analgesics. A statistically significant reduction in mean NRS was found at each follow-up visit ( p < .05). A total of 50 ADRs were observed. Constipation (38%) and drowsiness (24%) were the most frequently reported ADRs, with morphine and tramadol being the most common suspected causal drugs. Tramadol and morphine were frequently prescribed analgesics in patients with HNC pain in accordance with the WHO analgesic ladder. The majority of patients with HNC pain achieved a significant reduction in NRS pain scores at the end of six months.
头颈癌(HNC)占所有恶性肿瘤的 5%,但 80% 的患者会感到疼痛。根据世界卫生组织镇痛阶梯,镇痛药是治疗 HNC 患者疼痛的基石。我们的研究旨在分析 HNC 疼痛患者的镇痛药物处方模式。我们在 HNC 疼痛患者中开展了一项前瞻性、连续性、观察性研究。研究人员在基线随访、第一、第二和第六个月随访时记录了患者的人口统计学特征、详细的疼痛病史(类型、持续时间、部位和数值评定量表 [NRS] 评分)、处方药物的详细信息以及任何药物不良反应 (ADR)。对上述参数进行了描述性统计分析。用 Z 检验分析了 NRS 的平均下降幅度。在 145 名患者中,男性 118 人(81.37%),女性 27 人(18.62%)。患者的平均年龄为 51.89 + 7.07 岁。曲马多(81.37%)和吗啡(62.75%)是常用的处方镇痛药。阿米替林(20%)和普瑞巴林(19.31%)是常用的辅助镇痛药。在每次随访中,NRS 平均值均有统计学意义上的明显降低(P < .05)。共观察到 50 例不良反应。便秘(38%)和嗜睡(24%)是最常报告的不良反应,吗啡和曲马多是最常见的可疑致病药物。根据世界卫生组织的镇痛阶梯,曲马多和吗啡是 HNC 疼痛患者常用的处方镇痛药。大多数 HNC 疼痛患者的 NRS 疼痛评分在 6 个月后显著降低。
{"title":"Evaluation of Pharmacotherapy of Cancer \u2028Pain in Patients with Head and Neck Cancer \u2028at a Tertiary Care Teaching Hospital","authors":"Shyam Vacchani, Megha Shah, Chetna Desai, Priti Sanghvi","doi":"10.1177/0976500x241246414","DOIUrl":"https://doi.org/10.1177/0976500x241246414","url":null,"abstract":"Head and neck cancers (HNC) account for 5% of all malignant tumours, but 80% of patients experience pain. As per the WHO analgesic ladder, analgesics are a cornerstone for the management of pain in HNC patients. Our study aims to analyse the prescribing pattern of analgesic drugs in patients with HNC pain. A prospective, continuous, observational study was conducted among patients with HNC pain. Demographics, detailed history of pain (type, duration, location and Numerical Rating Scale [NRS] score), details of drugs prescribed and any adverse drug reactions (ADRs) were recorded at baseline visit and at first, second and sixth month follow-up. Descriptive statistics were used to analyse the above parameters. The mean reduction in NRS was analysed by the Z test. Out of 145 patients, 118 (81.37%) were male and 27 (18.62%) were female. The mean age of patients was 51.89 + 7.07 years. Tramadol (81.37%) followed by morphine (62.75%) were the commonly prescribed analgesics. Amitriptyline (20%) followed by pregabalin (19.31%) were commonly prescribed adjuvant analgesics. A statistically significant reduction in mean NRS was found at each follow-up visit ( p < .05). A total of 50 ADRs were observed. Constipation (38%) and drowsiness (24%) were the most frequently reported ADRs, with morphine and tramadol being the most common suspected causal drugs. Tramadol and morphine were frequently prescribed analgesics in patients with HNC pain in accordance with the WHO analgesic ladder. The majority of patients with HNC pain achieved a significant reduction in NRS pain scores at the end of six months.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":"35 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140980074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative Cardiopulmonary Complications in Smokers and Non-smokers Undergoing Elective Surgery: A Prospective Study 接受择期手术的吸烟者和非吸烟者的围手术期心肺并发症:前瞻性研究
Pub Date : 2024-05-08 DOI: 10.1177/0976500x241246412
Venumula Vikram Reddy, Dinakar Mallem, Sonnaila Rama Krishna, V. Kotra, Wen-Han Chooi, K. Goh, L. Ming, M. Kanakal, Syed Atif Abbas, Khairulanwar Husain
Background: Studies indicated that smoking alters the response to anesthetics and alters the outcome of perioperative care. A full understanding of the impact of smoking cessation to enhance surgical outcomes is pertinent. Purpose: This research aimed to compare perioperative cardiopulmonary complications in smokers and non-smokers during elective surgery under general anesthesia. We aimed to determine the incidence of complications in patients with a history of smoking, identify those at an increased risk, and assess the relationship between smoking duration and complications Methods: A total of 100 patients, comprising 50 smokers and 50 non-smokers, were enrolled in the study. Various parameters, including heart rate increase during intubation, severe coughing, bronchospasm, oral secretions, oxygen desaturation, reintubation, opioid antagonist use, pulmonary edema, and other cardiopulmonary events, were assessed perioperatively. Statistical analysis involved both continuous and categorical variables. For continuous variables, the Student’s t-test and the Mann–Whitney U test were used for normally and non-normally distributed data, respectively. For categorical variables, chi-squared tests were employed. Sub-group analysis assessed the influence of smoking duration on the measured parameters. Results: Smokers exhibited significantly higher incidences of severe coughing, heart rate elevation during intubation, and bronchospasm compared to non-smokers. Additionally, smokers experienced more pronounced oxygen desaturation throughout the perioperative period. Furthermore, a longer history of smoking was associated with an increased risk of complications, with individuals smoking for 10 or more years displaying a higher incidence of adverse events. Conclusion: Smokers, particularly those with extended smoking histories, are at an increased risk of cardiopulmonary complications during elective surgery under general anesthesia. Emphasizing preoperative optimization, meticulous airway management, and smoking cessation support is essential to mitigate these risks. The study underscores the significance of these measures for enhancing perioperative safety and calls for further research to explore the long-term impacts and patient satisfaction associated with these interventions. These steps are essential not only for perioperative care but also for long-term health benefits among this patient population.
背景:研究表明,吸烟会改变对麻醉剂的反应,并改变围手术期护理的结果。充分了解戒烟对提高手术效果的影响非常重要。目的:本研究旨在比较吸烟者和非吸烟者在全身麻醉下进行择期手术时的围术期心肺并发症。我们旨在确定有吸烟史的患者的并发症发生率,识别风险增加的患者,并评估吸烟时间与并发症之间的关系:研究共招募了 100 名患者,包括 50 名吸烟者和 50 名非吸烟者。围手术期评估了各种参数,包括插管时心率增快、剧烈咳嗽、支气管痉挛、口腔分泌物、氧饱和度降低、重新插管、阿片类拮抗剂的使用、肺水肿和其他心肺事件。统计分析包括连续变量和分类变量。对于连续变量,正态分布和非正态分布数据分别采用学生 t 检验和 Mann-Whitney U 检验。对于分类变量,则采用卡方检验。分组分析评估了吸烟时间对测量参数的影响。结果显示与非吸烟者相比,吸烟者严重咳嗽、插管时心率升高和支气管痉挛的发生率明显更高。此外,吸烟者在整个围手术期会出现更明显的氧饱和度降低。此外,吸烟史越长,发生并发症的风险越高,吸烟 10 年或 10 年以上者发生不良事件的几率更高。结论:吸烟者,尤其是有长期吸烟史的吸烟者,在全身麻醉下进行择期手术时发生心肺并发症的风险更高。强调术前优化、细致的气道管理和戒烟支持对降低这些风险至关重要。这项研究强调了这些措施对提高围手术期安全性的重要意义,并呼吁进一步开展研究,探讨这些干预措施的长期影响和患者满意度。这些措施不仅对围手术期护理至关重要,而且对这一患者群体的长期健康益处也至关重要。
{"title":"Perioperative Cardiopulmonary Complications in Smokers and Non-smokers Undergoing Elective Surgery: A Prospective Study","authors":"Venumula Vikram Reddy, Dinakar Mallem, Sonnaila Rama Krishna, V. Kotra, Wen-Han Chooi, K. Goh, L. Ming, M. Kanakal, Syed Atif Abbas, Khairulanwar Husain","doi":"10.1177/0976500x241246412","DOIUrl":"https://doi.org/10.1177/0976500x241246412","url":null,"abstract":"Background: Studies indicated that smoking alters the response to anesthetics and alters the outcome of perioperative care. A full understanding of the impact of smoking cessation to enhance surgical outcomes is pertinent. Purpose: This research aimed to compare perioperative cardiopulmonary complications in smokers and non-smokers during elective surgery under general anesthesia. We aimed to determine the incidence of complications in patients with a history of smoking, identify those at an increased risk, and assess the relationship between smoking duration and complications Methods: A total of 100 patients, comprising 50 smokers and 50 non-smokers, were enrolled in the study. Various parameters, including heart rate increase during intubation, severe coughing, bronchospasm, oral secretions, oxygen desaturation, reintubation, opioid antagonist use, pulmonary edema, and other cardiopulmonary events, were assessed perioperatively. Statistical analysis involved both continuous and categorical variables. For continuous variables, the Student’s t-test and the Mann–Whitney U test were used for normally and non-normally distributed data, respectively. For categorical variables, chi-squared tests were employed. Sub-group analysis assessed the influence of smoking duration on the measured parameters. Results: Smokers exhibited significantly higher incidences of severe coughing, heart rate elevation during intubation, and bronchospasm compared to non-smokers. Additionally, smokers experienced more pronounced oxygen desaturation throughout the perioperative period. Furthermore, a longer history of smoking was associated with an increased risk of complications, with individuals smoking for 10 or more years displaying a higher incidence of adverse events. Conclusion: Smokers, particularly those with extended smoking histories, are at an increased risk of cardiopulmonary complications during elective surgery under general anesthesia. Emphasizing preoperative optimization, meticulous airway management, and smoking cessation support is essential to mitigate these risks. The study underscores the significance of these measures for enhancing perioperative safety and calls for further research to explore the long-term impacts and patient satisfaction associated with these interventions. These steps are essential not only for perioperative care but also for long-term health benefits among this patient population.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":" 20","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140999254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ustekinumab: In Psoriasis and Beyond —A Derm atological Perspective Ustekinumab:银屑病及其他疾病--皮肤病学视角
Pub Date : 2024-05-08 DOI: 10.1177/0976500x241240643
Aditya Bubna, Vinayak Viplav
Background: Ustekinumab is an interleukin 12/23 inhibitor, approved by the US-FDA for the management of moderate-to-severe plaque psoriasis and psoriatic arthropathy. Purpose: This review aims to describe the dermatological implications and applications of ustekinumab. Methods: PubMed and Google Scholar were searched for scholarly articles related to ustekinumab and its utility in dermatology using the search terms “Ustekinumab” AND “Psoriasis” AND “dermatological diseases”. Studies utilising Ustekinumab in psoriasis and other dermatological indications were analysed and formulated into a systematic review discussing the utility of the drug in psoriasis, as well as other dermatological conditions. Results: Ustekinumab is a valuable biologic agent for the management of psoriasis and psoriatic arthropathy, as well as other dermatological disorders like hidradenitis suppurativa, lichen planus, pityriasis rubra pilaris, Behcet’s disease, lupus erythematosus, alopecia areata and pyoderma gangrenosum. Conclusion: Ustekinumab’s usage is not limited to psoriasis. Its benefit extends to many more dermatological conditions. It is considered to be the biologic of choice in childhood psoriasis and adult psoriatic patients with concurrent Crohn’s disease. Besides, it has an acceptable safety profile.
背景介绍乌斯特库单抗是一种白细胞介素 12/23 抑制剂,已获美国 FDA 批准用于治疗中重度斑块状银屑病和银屑病关节病。目的:本综述旨在描述乌斯特库单抗在皮肤病学方面的意义和应用。研究方法使用 "Ustekinumab"、"银屑病 "和 "皮肤病 "等关键词在 PubMed 和 Google Scholar 上搜索与乌司替尼及其在皮肤病学中的应用相关的学术文章。对使用 Ustekinumab 治疗银屑病和其他皮肤病适应症的研究进行了分析,并撰写了一篇系统综述,讨论该药物在银屑病和其他皮肤病中的应用。研究结果乌司他单抗是治疗银屑病和银屑病关节病以及其他皮肤病(如化脓性扁平苔藓、扁平苔藓、红斑狼疮、白塞氏病、红斑狼疮、斑秃和脓疱疮)的重要生物制剂。结论Ustekinumab 的用途不仅限于银屑病。它还能治疗更多的皮肤病。它被认为是治疗儿童银屑病和并发克罗恩病的成年银屑病患者的首选生物制剂。此外,它的安全性也是可以接受的。
{"title":"Ustekinumab: In Psoriasis and Beyond —A Derm atological Perspective","authors":"Aditya Bubna, Vinayak Viplav","doi":"10.1177/0976500x241240643","DOIUrl":"https://doi.org/10.1177/0976500x241240643","url":null,"abstract":"Background: Ustekinumab is an interleukin 12/23 inhibitor, approved by the US-FDA for the management of moderate-to-severe plaque psoriasis and psoriatic arthropathy. Purpose: This review aims to describe the dermatological implications and applications of ustekinumab. Methods: PubMed and Google Scholar were searched for scholarly articles related to ustekinumab and its utility in dermatology using the search terms “Ustekinumab” AND “Psoriasis” AND “dermatological diseases”. Studies utilising Ustekinumab in psoriasis and other dermatological indications were analysed and formulated into a systematic review discussing the utility of the drug in psoriasis, as well as other dermatological conditions. Results: Ustekinumab is a valuable biologic agent for the management of psoriasis and psoriatic arthropathy, as well as other dermatological disorders like hidradenitis suppurativa, lichen planus, pityriasis rubra pilaris, Behcet’s disease, lupus erythematosus, alopecia areata and pyoderma gangrenosum. Conclusion: Ustekinumab’s usage is not limited to psoriasis. Its benefit extends to many more dermatological conditions. It is considered to be the biologic of choice in childhood psoriasis and adult psoriatic patients with concurrent Crohn’s disease. Besides, it has an acceptable safety profile.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":" 14","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140999231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Review on Pharmacological Advancement of Ellagic Acid 鞣花酸药理研究进展综述
Pub Date : 2024-05-03 DOI: 10.1177/0976500x241240634
Pougang Golmei, Sweta Kasna, Kumar Probin Roy, Sachin Kumar
Background: In recent years, ellagic acid has emerged as a focal point in pharmacological research, showcasing promising developments and potential therapeutic applications as a competitive inhibitor of Src homology phosphotyrosyl phosphatase 2 for the treatment of cancer, as a shielding impact that stimulates sirtuin 6 (SIRT 6), against nephrotoxicity induced by cisplatin, as adjuvant treatment in sickle cell anemia, as antiaging and to avoid mild cognitive impairment. Purpose: This review provides a concise overview of the latest advancements in ellagic acid research, highlighting novel pharmacological findings and emerging trends. Methods: A comprehensive search of relevant literature was conducted to gather information on the pharmacological properties and therapeutic applications of ellagic acid. Studies investigating its antioxidant properties, anti-inflammatory effects, molecular interactions, and therapeutic implications were included in the analysis. Results: The review summarizes the multifaceted pharmacological landscape of ellagic acid, encompassing its antioxidant properties, anti-inflammatory effects, and potential therapeutic applications. It sheds light on its evolving role in modern medicine and underscores its significance as a promising avenue for future pharmaceutical exploration. Conclusion: The recent strides in ellagic acid development highlight its potential as a valuable therapeutic agent in various health conditions. Further research into its molecular interactions and clinical applications is warranted to fully harness its therapeutic potential and improve patient outcomes.
背景:近年来,鞣花酸已成为药理学研究的一个焦点,它作为治疗癌症的 Src 同源膦酰基磷酸酶 2 的竞争性抑制剂、刺激 sirtuin 6 (SIRT 6) 的屏蔽作用、顺铂诱导的肾毒性、镰状细胞性贫血的辅助治疗、抗衰老和避免轻度认知障碍等,都展示了其广阔的发展前景和潜在的治疗应用。目的:这篇综述简明扼要地概述了鞣花酸研究的最新进展,重点介绍了新的药理学发现和新兴趋势。研究方法对相关文献进行了全面检索,以收集有关鞣花酸药理特性和治疗应用的信息。分析包括有关鞣花酸抗氧化特性、抗炎作用、分子相互作用和治疗意义的研究。结果:综述总结了鞣花酸的多方面药理作用,包括其抗氧化特性、抗炎作用和潜在的治疗应用。它揭示了鞣花酸在现代医学中不断发展的作用,并强调了鞣花酸作为未来药物探索的一个重要途径的意义。结论:鞣花酸的最新发展突显了它作为治疗各种健康状况的重要药物的潜力。为了充分利用鞣花酸的治疗潜力并改善患者的治疗效果,有必要对其分子相互作用和临床应用进行进一步研究。
{"title":"A Review on Pharmacological Advancement of Ellagic Acid","authors":"Pougang Golmei, Sweta Kasna, Kumar Probin Roy, Sachin Kumar","doi":"10.1177/0976500x241240634","DOIUrl":"https://doi.org/10.1177/0976500x241240634","url":null,"abstract":"Background: In recent years, ellagic acid has emerged as a focal point in pharmacological research, showcasing promising developments and potential therapeutic applications as a competitive inhibitor of Src homology phosphotyrosyl phosphatase 2 for the treatment of cancer, as a shielding impact that stimulates sirtuin 6 (SIRT 6), against nephrotoxicity induced by cisplatin, as adjuvant treatment in sickle cell anemia, as antiaging and to avoid mild cognitive impairment. Purpose: This review provides a concise overview of the latest advancements in ellagic acid research, highlighting novel pharmacological findings and emerging trends. Methods: A comprehensive search of relevant literature was conducted to gather information on the pharmacological properties and therapeutic applications of ellagic acid. Studies investigating its antioxidant properties, anti-inflammatory effects, molecular interactions, and therapeutic implications were included in the analysis. Results: The review summarizes the multifaceted pharmacological landscape of ellagic acid, encompassing its antioxidant properties, anti-inflammatory effects, and potential therapeutic applications. It sheds light on its evolving role in modern medicine and underscores its significance as a promising avenue for future pharmaceutical exploration. Conclusion: The recent strides in ellagic acid development highlight its potential as a valuable therapeutic agent in various health conditions. Further research into its molecular interactions and clinical applications is warranted to fully harness its therapeutic potential and improve patient outcomes.","PeriodicalId":502944,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":"8 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141014671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pharmacology and Pharmacotherapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1